Related Experiment Videos
Determination of plasma ET-1 by RIA--risks and limitations
S M Baumgartner-Parzer1, P Nowotny, O Wagner
1Department of Internal Medicine III, University of Vienna, Austria. Sabina.Baumgartner-Parzer@akh-wien.ac.at
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|December 16, 1998
Summary
Measuring endothelin-1 (ET-1) peptide levels in plasma is inconsistent across different commercial radioimmunoassays. Plasma ET-1 concentrations vary significantly based on the assay method used, requiring careful interpretation of results.
Area of Science:
- Biochemistry
- Endocrinology
- Clinical Chemistry
Background:
- Endothelin-1 (ET-1) is a potent vasoconstrictor peptide with significant physiological roles.
- Accurate measurement of plasma ET-1 is crucial for understanding various pathological conditions.
Purpose of the Study:
- To evaluate the variability of plasma endothelin-1 (ET-1) measurements using different commercial radioimmunoassays (RIAs).
- To assess the impact of assay methodology on reported ET-1 concentrations.
Main Methods:
- Plasma samples from healthy subjects and patients were analyzed.
- Three distinct commercially available radioimmunoassays (RIAs) were employed.
- Standard prepurification protocols recommended for each RIA were followed.
Main Results:
- Significant differences in measured ET-1 concentrations were observed across the different RIAs.
- The choice of antibody and extraction procedure directly influenced the determined ET-1 levels.
- Identical plasma samples yielded disparate results depending on the assay used.
Conclusions:
- Plasma endothelin-1 (ET-1) concentrations obtained via RIA are apparent values, not absolute.
- Results from different ET-1 assays are not directly comparable.
- Caution is advised when interpreting plasma ET-1 concentrations due to assay-dependent variability.